Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma

Figure 3

GO and pathway analysis of mRNA from cisplatin resistance in lung adenocarcinoma. (a) Biological processes of downregulated mRNA. (b) Cellular components of downregulated mRNA. (c) Molecular functions of downregulated mRNA. (d) Biological processes of upregulated mRNA. (e) Cellular components of upregulated mRNA. (f) Molecular functions of upregulated mRNA. (g) Pathway analysis of downregulated mRNA from cisplatin resistance in lung adenocarcinoma. (h) Pathway analysis of upregulated mRNA from cisplatin resistance in lung adenocarcinoma.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)